Animal Models of Non-Alcoholic Steatohepatitis: Of Mice and Man
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
The epidemic occurrence of obesity has led to a rapid increase in the incidence of non-alcoholic fatty liver disease (NAFLD) in industrial countries. The disease spectrum includes hepatic steatosis, lobular inflammation with steatohepatitis (NASH) and varying degrees of liver fibrosis, which can progress to cirrhosis. Hepatocellular carcinoma can develop in patients with NASH, even in the absence of cirrhosis. The majority of patients with primary NASH exhibit risk factors that define the metabolic syndrome including insulin resistance and visceral obesity. However, only a minority of patients with NAFLD progress to end-stage liver disease and, so far, predictors to identify these patients are not available. The course of disease progression appears to be slow and develops progressively over years, modulated by genetic susceptibility, nutritional misbehavior and environmental factors. Although risk factors have been identified in epidemiological studies, little is known about disease initiation and progression. This review summarizes the existing animal models of NAFLD, focusing on genetic and dietary models, and discusses their applicability in studying signaling events involved in steatohepatitis. Despite the shortcomings inherent to all experimental models, research in this field has helped to identify potential therapeutic targets and, thus, contributed significantly to our understanding of this disease. The validation and search for new in vivo and in vitro models will propagate the understanding of NASH and help clinicians to develop new treatment modalities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P., Horton, J. D., Cohen, J. C., Grundy, S. M., & Hobbs, H. H. (2004) · Hepatology · doi:10.1002/hep.20466 · Cited by 3,664
Ludwig, J., Viggiano, T. R., McGill, D. B., & Ott, B. J. (1980) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(24)00530-5 · Cited by 2,903
Chen, H., Charlat, O., Tartaglia, L. A., Woolf, E. A., Weng, X., Ellis, S. J., Lakey, N. D., Culpepper, J., More, K. J., Breitbart, R. E., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81294-5 · Cited by 2,214
Peroxisome proliferator–activated receptor α mediates the adaptive response to fasting
Kersten, S., Seydoux, J., Peters, J. M., Gonzalez, F. J., Desvergne, B., & Wahli, W. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6223 · Cited by 1,649
Physiological response to long-term peripheral and central leptin infusion in lean and obese mice.
Halaas, J. L., Boozer, C., Blair-West, J., Fidahusein, N., Denton, D. A., & Friedman, J. M. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.16.8878 · Cited by 1,033
Metabolic syndrome and hepatocellular carcinoma: Two growing epidemics with a potential link
Siegel, A. B., & Zhu, A. X. (2009) · Cancer · doi:10.1002/cncr.24687 · Cited by 399 · cited 1×
“Additionally, fatty liver can act as a cofactor in acute or chronic liver disease and augments the vulnerability of hepatocytes to secondary injurious insults by decreasing anti-oxidant capacities and increased activation of pro-injurious signaling pathways. The occurrence of hepatocellular carcinoma (HCC) in patients…”
JNK1 but not JNK2 promotes the development of steatohepatitis in mice
Schattenberg, J. M., Singh, R., Wang, Y., Lefkowitch, J. H., Rigoli, R. M., Scherer, P. E., & Czaja, M. J. (2006) · Hepatology · doi:10.1002/hep.20999 · Cited by 384
Fan, C.-Y., Pan, J., Usuda, N., Yeldandi, A. V., Rao, M. S., & Reddy, J. K. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.25.15639 · Cited by 343 · cited 1×
“The straight-chain acyl-CoA oxidase oxidizes long-chain fatty acids and is the first rate-limiting enzyme of peroxisomal β-oxidation. Loss of acyl-CoA oxidase results in severely increased levels of very-long-chain fatty acids with hepatomegaly, microvesicular steatohepatitis and lipogranulomas [”
BackgroundNF-κB signaling, liver disease and hepatoprotective agents
Sun, B., & Karin, M. (2008) · Oncogene · doi:10.1038/onc.2008.300 · Cited by 307
Sahai, A., Malladi, P., Pan, X., Paul, R., Melin-Aldana, H., Green, R. M., & Whitington, P. F. (2004) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00199.2004 · Cited by 290 · cited 1×
“Hyperleptinemia, due to a loss of the leptin receptor as seen in db/db or fa/fa mice, resembles the human condition more closely. However, these animals also develop only a mild form of steatohepatitis without significant amounts of liver cell injury, and secondary injurious stimuli are commonly used to induce cell de…”
BackgroundHepatocyte CYP2E1 overexpression and steatohepatitis lead to impaired hepatic insulin signaling
Schattenberg, J. M., Wang, Y., Singh, R., Rigoli, R. M., & Czaja, M. J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m410310200 · Cited by 194 · cited 1×
“However, studies of hepatic insulin signaling pathways revealed that the MCD diet decreases hepatic insulin sensitivity involving oxidative stress and c-Jun N -terminal kinase (JNK) activation and prevents activation of downstream mediators and transcription factors of insulin signaling in hepatocytes [”
BackgroundNakayama, H., Otabe, S., Ueno, T., Hirota, N., Yuan, X., Fukutani, T., Hashinaga, T., Wada, N., & Yamada, K. (2007) · Metabolism · doi:10.1016/j.metabol.2006.11.004 · Cited by 79
Cited by
Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease
Ipsen, D. H., Lykkesfeldt, J., & Tveden-Nyborg, P. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2860-6 · Cited by 1,471
Csak, T., Ganz, M., Pespisa, J., Kodys, K., Dolganiuc, A., & Szabo, G. (2011) · Hepatology · doi:10.1002/hep.24341 · Cited by 645
Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
Takahashi, Y. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i19.2300 · Cited by 554
In Vitro and in Vivo Models of Non-Alcoholic Fatty Liver Disease (NAFLD)
Kanuri, G., & Bergheim, I. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140611963 · Cited by 290
Experimental models of non-alcoholic fatty liver disease in rats
Kucera, O. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i26.8364 · Cited by 195
Metadata
- Authors
- Schattenberg, J. M., & Galle, P. R.
- Venue
- Digestive Diseases
- Publisher
- S. Karger AG
- Published
- 2010
- Volume
- 28
- Issue
- 1
- Pages
- 247-254
- ISSN
- 0257-2753 (ISSN-L)
- 1421-9875
- OpenAlex
- W2073438109
- Cited by
- 140
- References
- 12
- FWCI
- 8.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.